Nanoparticles for combined photo- and chemo-dynamic therapy of cancer cells involving endogenous glutathione depletion
Abstract
Background: Reactive oxygen species (ROS) are powerful weapons for various anticancer therapies. However, high glutathione (GSH) levels in cancer cells can significantly reduce the efficacy of such therapies. Methods: In this study, pH-responsive fluorescein-encapsulated zeolitic imidazolate framework-8 nanoparticles were synthesized for ROS-mediated combination therapy. Results: Upon blue light activation, fluorescein displayed a high singlet oxygen photogeneration ability for photodynamic therapy. Concurrently, accumulated Zn2+ from degraded zeolitic imidazolate framework-8 stimulated simultaneous ROS generation and GSH depletion, thereby successfully inducing chemodynamic therapy. This triggered a cascade of photo–physical and chemical processes culminating in the localized generation of ROS, ultimately breaking the intracellular redox equilibrium. Conclusion: This nanoformulation can potentially be used for light-activated ROS-mediated therapy for the management of superficial tumors.
Plain language summary
Highly reactive molecules called reactive oxygen species (ROS) are known to be present in excess in cancer cells. As a result, cancer cells are more susceptible to death by any further rise in levels of these species. In the current study, fluorescein-encapsulated zeolitic imidazolate nanoparticles were prepared for blue light-activated ROS-enhancing combination therapy. The nanoparticles displayed significant toxicity against a breast cancer cell line and simultaneously induced glutathione depletion, an antioxidant known to reduce the efficacy of various cancer therapies. Thus, this study reveals the potential of fluorescein-encapsulated zeolitic imidazolate nanoparticles for light-activated ROS-mediated therapy for the treatment of superficial tumors.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. WHO. WHO Cancer. www.who.int/en/news-room/fact-sheets/detail/cancer
- 2. . Photodynamic therapy in cancer treatment – an update review. J. Cancer Metastasis Treat. 5, 25 (2019).
- 3. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 61(4), 250–281 (2011).
- 4. Advances in nanomaterials for photodynamic therapy applications: status and challenges. Biomaterials 237, 119827 (2020).
- 5. ROS in cancer therapy: the bright side of the moon. Exp. Mol. Med. 52(2), 192–203 (2020).
- 6. The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res. 37, 266 (2018).
- 7. . Recent advances of cancer chemodynamic therapy based on Fenton/Fenton-like chemistry. Chem. Sci. 13(4), 863–889 (2022).
- 8. . Chemodynamic therapy: tumour microenvironment-mediated Fenton and Fenton-like reactions. Angew. Chem. Int. Ed. 58(4), 946–956 (2019).
- 9. . Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat. Rev. Clin. Oncol. 17(11), 657–674 (2020).
- 10. . Type I AIE photosensitizers: mechanism and application. View 3(2), 20200121 (2021).
- 11. Metal-free polymer nano-photosensitizer actuates ferroptosis in starved cancer. Biomaterials 292, 121944 (2023).
- 12. Manganese-based nanoplatform as metal ion-enhanced ROS generator for combined chemodynamic/photodynamic therapy. ACS Appl. Mater. Interfaces 11(44), 41140–41147 (2019).
- 13. O2-Cu/ZIF-8@Ce6/ZIF-8@F127 composite as a tumor microenvironment-responsive nanoplatform with enhanced photo-/chemodynamic antitumor efficacy. ACS Appl. Mater. Interfaces 11(35), 31671–31680 (2019).
- 14. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res. 62(1), 307–312 (2002).
- 15. Glutathione-responsive PLGA nanocomplex for dual delivery of doxorubicin and curcumin to overcome tumor multidrug resistance. Nanomedicine 16(16), 1411–1427 (2021).
- 16. Radiotherapy-mediated redox homeostasis-controllable nanomedicine for enhanced ferroptosis sensitivity in tumor therapy. Acta Biomater. 159, 300–311 (2023).
- 17. Multifunctional MnO2-based nanoplatform-induced ferroptosis and apoptosis for synergetic chemoradiotherapy. Nanomedicine 16(26), 2343–2361 (2021).
- 18. . Biomedical applications of metal organic frameworks. Ind. Eng. Chem. Res. 50(4), 1799–1812 (2011).
- 19. . Metal-organic frameworks for drug delivery: a design perspective. ACS Appl. Mater. Interfaces 13(6), 7004–7020 (2021).
- 20. . Zeolitic imidazolate framework materials: recent progress in synthesis and applications. J. Mater. Chem. A 2(40), 16811–16831 (2014).
- 21. . Synthesis, structure, and carbon dioxide capture properties of zeolitic imidazolate frameworks. ACC Chem. Res. 43(1), 58–67 (2010).
- 22. . Mechanistic interaction studies of synthesized ZIF-8 nanoparticles with bovine serum albumin using spectroscopic and molecular docking approaches. Sci. Rep. 12, 10331 (2022).
- 23. Zeolitic imidazolate framework-8 as efficient pH-sensitive drug delivery vehicle. Dalton Trans. 41(23), 6906–6909 (2012).
- 24. . Size- and dose-dependent cytotoxicity of ZIF-8 based on single cell analysis. Ecotoxicol. Environ. Saf. 205, 111110 (2020). •• Increased accumulation of zinc ions due to the high bioavailability of zeolitic imidazolate framework-8 results in enhanced reactive oxygen species generation.
- 25. Dual roles of metal-organic frameworks as nanocarriers for miRNA delivery and adjuvants for chemodynamic therapy. ACS Appl. Mater. Interfaces 13(5), 6034–6042 (2021). • Reports that zinc ions triggered reactive oxygen species generation by zeolitic imidazolate framework-8 nanoparticles for chemodynamic therapy.
- 26. ZIF-8 nanoparticles induce neurobehavioral disorders through the regulation of ROS-mediated oxidative stress in zebrafish embryos. Chemosphere 305, 135453 (2022).
- 27. . Fluorescein-metal hybrid surfactant conjugates as a smart material for antimicrobial photodynamic therapy against Staphylococcus aureus. ACS Appl. Bio. Mater. 3(7), 4674–4683 (2020).
- 28. WHO. WHO model list of essential medicines – 22nd list (2021). www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02
- 29. . Light sources and dosimetry techniques for photodynamic therapy. Photochem. Photobiol. 96(2), 280–294 (2020).
- 30. Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes in human colon cancer cells. Oncol. Rep. 29(3), 911–916 (2013).
- 31. . Effects of LED-based photodynamic therapy using red and blue lights, with natural hydrophobic photosensitizers on human glioma cell line. Photodiag. Photodyn. Ther. 21, 50–54 (2018).
- 32. Blue light irradiation inhibits the growth of colon cancer and activation of cancer-associated fibroblasts. Oncol. Rep. 47(5), 104 (2022). • Study showing antitumor effects of blue light-emitting diode light on colon cancer.
- 33. . Optimized metal-organic framework nanospheres for drug delivery: evaluation of small-molecule encapsulation. ACS Nano 8(3), 2812–2819 (2014). • Study reporting general synthesis route for encapsulating small molecules such as fluorescein and camptothecin in zeolitic imidazolate framework-8 nanospheres.
- 34. . In situ high pressure study of ZIF-8 by FTIR spectroscopy. Chem. Commun. 47(47), 12694–12696 (2011).
- 35. Adsorption in a fixed-bed column and stability of the antibiotic oxytetracycline supported on Zn(II)-[2-methylimidazolate] frameworks in aqueous media. PLOS ONE 10(6), e0128436 (2015).
- 36. . Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol. Appl. Pharmacol. 241(2), 163–172 (2009).
- 37. . Analysis of hypoxia-induced metabolic reprogramming. Methods Enzymol. 542, 425–455 (2014).
- 38. . The endocytosis and intracellular fate of nanomedicines: implication for rational design. Asian J. Pharm. Sci. 8(1), 1–10 (2013).
- 39. . Lipid rafts, caveolae, and their endocytosis. Int. Rev. Cell Mol. Biol. 282, 135–163 (2010).
- 40. . Lovastatin. In: The Comprehensive Pharmacology Reference. Enna SJBylund DB (Eds). Elsevier, Amsterdam, The Netherlands, 1–5 (2007).
- 41. . Mechanisms of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 19(5), 313–326 (2018).
- 42. Selectivity of commonly used inhibitors of clathrin-mediated and caveolae-dependent endocytosis of G protein-coupled receptors. Biochim. Biophys. Acta Biomembr. 1848(10), 2101–2110 (2015).
- 43. . Inhibitors of clathrin-dependent endocytosis enhance TGFβ signaling and responses. J. Cell Sci. 122(11), 1863–1871 (2009).
- 44. Exocytosis and endocytosis. In: Methods in Molecular Biology: Volume 440. Ivanov AI (Ed.). Human Press, NY, USA, 247–257 (2008).
- 45. . Effects of endocytosis inhibitors on internalization of human IgG by Caco-2 human intestinal epithelial cells. Life Sci. 85(23-26), 800–807 (2009).
- 46. . Studies of endocytosis. In: Dendritic Cells (2nd Edition). Lotze MThomson A (Eds). Academic Press, Amsterdam, The Netherlands, 213–229 (2001).
- 47. . Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLOS ONE 6(9), e24438 (2011).
- 48. MOF nanoparticles with encapsulated autophagy inhibitor in controlled drug delivery system for antitumor. ACS Appl. Mater. Interfaces 10(3), 2328–2337 (2018).
- 49. Disassembly of hydrophobic photosensitizer by biodegradable zeolitic imidazolate framework-8 for photodynamic cancer therapy. ACS Appl. Mater. Interfaces 10(18), 15517–15523 (2018).
- 50. . Characterization techniques for nanoparticles: comparison and complementarity upon studying nanoparticle properties. Nanoscale 10(27), 12871–12934 (2018).
- 51. . Controlling ZIF-8 nano- and microcrystal formation and reactivity through zinc salt variations. CrystEngComm 16(21), 4493–4500 (2014).
- 52. Improving the acidic stability of zeolitic imidazolate frameworks by biofunctional molecules. Chem 5(6), 1597–1608 (2019).
- 53. . ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 7(2), 97–110 (2004).
- 54. . Real time monitoring and quantification of reactive oxygen species in breast cancer cell line MCF-7 by 2′,7′-dichlorofluorescein diacetate (DCFDA) assay. J. Pharmacol. Toxicol. Methods 94(Pt 1), 26–33 (2018).
- 55. . Quantification of lactate dehydrogenase for cell viability testing using cell lines and primary cultured astrocytes. Curr. Protoc. Toxicol. 72, 2.26.1–2.26.10 (2017).
- 56. . The role of nitric oxide in cancer. Cell Res. 12(5-6), 311–320 (2002).
- 57. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol. Lett. 4(6), 1247–1253 (2012).
- 58. Role of glutathione in cancer progression and chemoresistance. Oxid. Med. Cell Longev. 2013, 972913 (2013). •• Role of glutathione depletion in sensitizing cancer cells to therapy.
- 59. A self-amplifying nanodrug to manipulate the Janus-faced nature of ferroptosis for tumor therapy. Nanoscale Horiz. 7(2), 198–210 (2022).
- 60. . Studies of zinc(II) and nickel(II) complexes of GSH, GSSG and their analogs shed more light on their biological relevance. Bioinorg. Chem. Appl. 2(3-4), 293–305 (2004).
- 61. . Stability of zinc complexes with glutathione and oxidized glutathione. J. Am. Chem. Soc. 76(1), 225–229 (1954).
- 62. . Development of antioxidant and xenobiotic metabolizing enzyme systems. In: The Lung. Harding RPinkerton KEPlopper CG (Eds). Elsevier, Academic Press, CA, USA, 177–185 (2004).
- 63. . The role of glutathione reductase and related enzymes on cellular redox homeostasis network. Free Radic. Biol. Med. 95, 27–42 (2016).
- 64. . Plasma glutathione S-transferase measurements after paracetamol overdose: evidence for early hepatocellular damage. Gut 26(1), 26–31 (1985).
- 65. . Bioconjugation of silk fibroin nanoparticles with enzyme and peptide and their characterization. In: Advances in Protein Chemistry and Structural Biology: Volume 98. Donev R (Ed.). Elsevier, Academic Press, MA, USA, 263–291 (2015).
- 66. Fluorescein-based type I supramolecular photosensitizer via induction of charge separation by self-assembly. JACS Au 2(6), 1472–1478 (2022).
- 67. . Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat. Res. Fundam. Mol. Mech. Mutagenes 531(1-2), 81–92 (2003). •• Role of ‘free’ cellular iron in inducing oxidative damage by participating in a Fenton reaction.
- 68. . Iron-sulfur cluster biogenesis as a critical target in cancer. Antioxidants (Basel) 10(9), 1458 (2021).